Market capitalization | JPY706.07b |
Enterprise Value | JPY649.45b |
P/E (TTM) P/E ratio | 14.11 |
EV/FCF (TTM) EV/FCF | 8.43 |
EV/Sales (TTM) EV/Sales | 1.33 |
P/S ratio (TTM) P/S ratio | 1.45 |
P/B ratio (TTM) P/B ratio | 0.90 |
Dividend yield | 5.32% |
Last dividend (FY26) | JPY80.00 |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
10 Analysts have issued a Ono Pharmaceutical forecast:
10 Analysts have issued a Ono Pharmaceutical forecast:
Mar '25 |
+/-
%
|
||
Revenue | 486,871 486,871 |
3%
3%
|
|
Gross Profit | 338,921 338,921 |
11%
11%
|
|
EBITDA | 90,278 90,278 |
52%
52%
|
EBIT (Operating Income) EBIT | 63,384 63,384 |
62%
62%
|
Net Profit | 50,047 50,047 |
61%
61%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of internal medicine, patch and injectable medicine. The company was founded by Ichibei Fushimiya in 1717 and is headquartered in Osaka, Japan.
Head office | Japan |
CEO | Gyo Sagara |
Founded | 1947 |
Website | www.ono.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.